Lipoprotein (a) is a predictor of non-achievement of LDL-C goals in patients with chronic heart disease

José Javier Gómez-Barrado; Paula Gómez-Turégano; María Beltrán Moreno; Ana Isabel Fernández-Chamorro; Benjamín Roque Rodríguez; Zineb Kounka

doi:10.1016/j.arteri.2024.01.002

Lipoprotein (a) is a predictor of non-achievement of LDL-C goals in patients with chronic heart disease

Clin Investig Arterioscler. 2024 Feb 23:S0214-9168(24)00006-8. doi: 10.1016/j.arteri.2024.01.002. Online ahead of print.

[Article in English, Spanish]

Authors

José Javier Gómez-Barrado¹, Paula Gómez-Turégano², María Beltrán Moreno², Ana Isabel Fernández-Chamorro², Benjamín Roque Rodríguez², Zineb Kounka²

Affiliations

¹ Departamento de Cardiología, Hospital Universitario San Pedro de Alcántara, Cáceres, España. Electronic address: jjgomezbarrado@gmail.com.
² Departamento de Cardiología, Hospital Universitario San Pedro de Alcántara, Cáceres, España.

PMID: 38402025
DOI: 10.1016/j.arteri.2024.01.002

Abstract

Introduction and objectives: Lipoprotein (a) [Lp(a)] concentration influences serum low-density lipoprotein cholesterol (LDL-C) levels. How it influences the achievement of LDL-C targets established in the guidelines is not well studied. Our aim was to know the prevalence of elevated Lp(a) levels in patients with coronary artery disease, and to assess its influence on the achievement of LDL-C targets.

Method: We conducted a cross-sectional study in a cardiology department in Spain. A total of 870 patients with stable coronary artery disease had their lipid profile determined, including Lp(a). Patients were stratified into 2 groups according to Lp(a)>50mg/dL and Lp(a)≤50mg/dL. The association of Lp(a)>50mg/dL with achievement of LDL-C targets was assessed by logistic regression analysis.

Results: The prevalence of Lp(a)>50mg/dL was 30.8%. Patients with Lp(a)>50mg/dL had higher baseline (142.30±47.54 vs. 130.47±40.75mg/dL; p=0.0001) and current (72.91±26.44 vs. 64.72±25.30mg/dL; p=0.0001), despite the fact that they were treated with more high-potency statins (77.2 vs. 70.9%; p=0.058) and more combination lipid-lowering therapy (37.7 vs. 25.7%; p=0.001). The proportion of patients achieving target LDL-C was lower in those with Lp(a)>50mg/dL. Independent predictors of having elevated Lp(a) levels>50mg/dL were the use of high-potency statins (OR 1.5; 95% CI 1.08-2.14), combination lipid-lowering therapy with ezetimibe (OR 2.0; 95% CI 1.45-2.73) and failure to achieve a LDL-C ≤55mg/dL (OR 2.3; 95% CI 1.63-3.23).

Conclusions: Elevated Lp(a) levels influence LDL-C levels and hinder the achievement of targets in patients at very high cardiovascular risk. New drugs that act directly on Lp(a) are needed in these patients.

Keywords: Colesterol-LDL; Coronary artery disease; Enfermedad arterial coronaria; LDL-cholesterol; Lipid-lowering treatment; Lipoprotein (a); Lipoproteína (a); Tratamiento hipolipidemiante.